ArticleObesity pillars2024
Optimizing nutrition, diet, and lifestyle communication in GLP-1 medication therapy for weight management: A qualitative research study with registered dietitians.
Article in Obesity pillars, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
12 citing papers in PubMed, 1 synthesis or guideline pooled it.
- The effect of obesity interventions on male fertility: a systematic review and meta-analysis.Human reproduction update · 2026Pooled it
- Digital Microsteps as Scalable Adjuncts for Adults Using GLP-1 Receptor Agonists: A Randomized Clinical Trial.JAMA network open · 2026Trial
- Review
- Review
- Nutritional and lifestyle supportive care recommendations for management of obesity with GLP-1 - based therapies: An expert consensus statement using a modified Delphi approach.Obesity pillars · 2026Review
- Pharmacological intervention: Challenges and promising outcomes for fat loss and preservation of lean body mass in the treatment of overweight and type 2 diabetes.Diabetes, obesity & metabolism · 2026Review
- Application of nutrition interventions with GLP-1 based therapies: A narrative review of the challenges and solutions.Obesity pillars · 2025Review
- Dietary supplement considerations during glucagon-like Peptide-1 receptor agonist treatment: A narrative review.Obesity pillars · 2025Review
- Injectable drugs for weight management.Australian prescriber · 2025Review
- What is the Role of Primary Prevention of Obesity in an Age of Effective Pharmaceuticals?Current obesity reports · 2025Review
- Investigating nutrient intake during use of glucagon-like peptide-1 receptor agonist: a cross-sectional study.Frontiers in nutrition · 2025Article
- ESI Clinical Practice Guidelines for the Evaluation and Management of Obesity in India - An Update (2025).Indian journal of endocrinology and metabolismArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: This qualitative study used semi-structured interviews to examine registered dietitians' perspectives on diet, nutrition, and lifestyle communication for patients on GLP-1 medications for obesity management. Methods: Through in-depth interviews with registered dietitians, this research identifies elements that could improve both the efficacy of GLP-1 medication therapies and patient adherence. Results: indicate that a comprehensive approach, integrating patient communication with proactive management of side effects and ongoing lifestyle counseling, is essential for optimizing treatment outcomes. Conclusion: Key findings include the importance of using visual and metaphorical aids to improve understanding, the necessity for structured lifestyle programs, and the pivotal role of personalized diet plans. These insights offer valuable directions for enhancing patient care and formulating clinical practices around the use of GLP-1 receptor agonist medications.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.